Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
NCT00604461 is a phase 1/2 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. As of 18 Nov 2026, it was terminated. It studies Carboplatin in Mesothelioma. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2007 and a primary completion date of 31 Jan 2011.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00604461 |
| Status | Terminated |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Enrollment | 13 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Mesothelioma |
| Drugs | Carboplatin |
| Start | 31 Oct 2007 |
| Primary completion | 31 Jan 2011 |
| Study completion | 31 Jan 2011 |
| Last update posted | 23 Mar 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Tawee Tanvetyanon, M.D.
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center & Research Institute
Tampa
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00604461
Each answer restates registry values shown on this page.
What is NCT00604461?
NCT00604461 is a phase 1/2 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. It studies Carboplatin in Mesothelioma.
Who leads NCT00604461?
The registry names Tawee Tanvetyanon, M.D. (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) as the overall official.
Where does NCT00604461 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00604461 study?
The registered drug and biological interventions are Carboplatin.
When did NCT00604461 end?
The registry lists a primary completion date of 31 Jan 2011 and a study completion date of 31 Jan 2011. The sponsor last updated the record on 23 Mar 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.